Klotho Neurosciences, Inc. (KLTO) has an overall financial health rating of D+ with a composite score of 0 out of 5.
This suggests the company faces some financial challenges worth monitoring. Rating as of 2026-03-17.
| Date | Rating | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|
| 2026-03-17 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2026-03-16 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2026-03-11 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2026-03-10 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2026-03-09 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2026-03-06 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2026-03-05 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2026-03-04 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2026-03-03 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2026-03-02 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2026-02-27 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2026-02-26 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 |
